Compounds > n-methyl-n-2-(methylsulfinyl)ethylpropionic acid amide
Page last updated: 2024-09-03

n-methyl-n-2-(methylsulfinyl)ethylpropionic acid amide and Lung Neoplasms

n-methyl-n-2-(methylsulfinyl)ethylpropionic acid amide has been researched along with Lung Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Jiang, Q; Luo, J; Ou, S; Peng, R; Qin, X; Wang, S; Wei, H1

Other Studies

2 other study(ies) available for n-methyl-n-2-(methylsulfinyl)ethylpropionic acid amide and Lung Neoplasms

ArticleYear
Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020.
    Frontiers in public health, 2023, Volume: 11

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Medical Oncology

2023
[China clinical practice guideline for epidermal growth factor receptor tyrosine kinase inhibitors in stage Ⅳ non-small cell lung cancer (version 2023)].
    Zhonghua yi xue za zhi, 2023, Oct-31, Volume: 103, Issue:40

    Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors

2023